DIA
Drug Information Association Logo
« Back to Listing

Capital Efficient Drug Development with Revolutionary Technologies: Calculated Risks

Track:
Professional Development

Day & Time:
June 17, 8:00AM - 9:30AM (Pacific Standard Time)

Session Number:
223

Room Number:
11B

Level:
Intermediate

Type:
Session

Title:
Capital Efficient Drug Development with Revolutionary Technologies: Calculated Risks

Chair(s):
Robert Wright, MBA
Chief Editor
Life Science Connect, United States

Description:
Being willing to take risks is essential to innovation. Calculated risk involves considerable analysis and market understanding but also requires passion, guts, perseverance, and constant reassessment and willingness to change course. This session will address how life science leaders must focus on practical translation of the science while being mindful of the convergence of multiple disciplines like ethics, information technology, and economics.

Learning Objective(s):
Define calculated risk; Describe potential roadblocks to bringing a disruptive technology to the market; Outline key decisions that mitigate risk and allow you to advance in a capital efficient manner.

Presentation(s) & Speaker(s):
Build It and They Will Come, Won't They?
Leslie J. Williams
Director, Founder, President and Chief Executive Officer
ImmusanT, United States

Tale of Two Pharmas
Keith Murphy
Chairman and Chief Executive Officer
Organovo, Inc., United States

Plans, People and Process
Laurie A. Halloran, BSN, MS
President and Chief Executive Officer
Halloran Consulting Group, Inc., United States